nodes	percent_of_prediction	percent_of_DWPC	metapath
Temsirolimus—MTOR—breast cancer	0.236	0.618	CbGaD
Temsirolimus—CYP2D6—breast cancer	0.0568	0.149	CbGaD
Temsirolimus—CYP3A4—breast cancer	0.0487	0.128	CbGaD
Temsirolimus—ABCB1—breast cancer	0.0406	0.106	CbGaD
Temsirolimus—CYP3A5—Lapatinib—breast cancer	0.0187	0.0549	CbGbCtD
Temsirolimus—ABCB1—Toremifene—breast cancer	0.0167	0.049	CbGbCtD
Temsirolimus—CYP3A4—Exemestane—breast cancer	0.0144	0.0424	CbGbCtD
Temsirolimus—CYP2D6—Idarubicin—breast cancer	0.013	0.0383	CbGbCtD
Temsirolimus—CYP3A7-CYP3A51P—Tamoxifen—breast cancer	0.0125	0.0367	CbGbCtD
Temsirolimus—CYP3A7—Tamoxifen—breast cancer	0.0125	0.0367	CbGbCtD
Temsirolimus—CYP3A4—Letrozole—breast cancer	0.0122	0.036	CbGbCtD
Temsirolimus—ABCB1—Lapatinib—breast cancer	0.0122	0.0357	CbGbCtD
Temsirolimus—CYP3A4—Anastrozole—breast cancer	0.0109	0.0321	CbGbCtD
Temsirolimus—CYP3A4—Toremifene—breast cancer	0.00999	0.0294	CbGbCtD
Temsirolimus—CYP3A7—Paclitaxel—breast cancer	0.00971	0.0285	CbGbCtD
Temsirolimus—CYP3A7-CYP3A51P—Paclitaxel—breast cancer	0.00971	0.0285	CbGbCtD
Temsirolimus—CYP3A7-CYP3A51P—Irinotecan—breast cancer	0.00958	0.0281	CbGbCtD
Temsirolimus—CYP3A7—Irinotecan—breast cancer	0.00958	0.0281	CbGbCtD
Temsirolimus—CYP3A5—Tamoxifen—breast cancer	0.00935	0.0275	CbGbCtD
Temsirolimus—CYP3A4—Fulvestrant—breast cancer	0.00928	0.0273	CbGbCtD
Temsirolimus—CYP3A4—Thiotepa—breast cancer	0.00827	0.0243	CbGbCtD
Temsirolimus—CYP3A4—Ixabepilone—breast cancer	0.00757	0.0222	CbGbCtD
Temsirolimus—CYP3A4—Lapatinib—breast cancer	0.00728	0.0214	CbGbCtD
Temsirolimus—CYP3A5—Paclitaxel—breast cancer	0.00728	0.0214	CbGbCtD
Temsirolimus—CYP3A5—Irinotecan—breast cancer	0.00718	0.0211	CbGbCtD
Temsirolimus—CYP3A7—Docetaxel—breast cancer	0.00702	0.0206	CbGbCtD
Temsirolimus—CYP3A7-CYP3A51P—Docetaxel—breast cancer	0.00702	0.0206	CbGbCtD
Temsirolimus—ABCB1—Vinorelbine—breast cancer	0.00674	0.0198	CbGbCtD
Temsirolimus—CYP2D6—Vinorelbine—breast cancer	0.00635	0.0187	CbGbCtD
Temsirolimus—ABCB1—Tamoxifen—breast cancer	0.00609	0.0179	CbGbCtD
Temsirolimus—ABCB1—Mitoxantrone—breast cancer	0.00594	0.0175	CbGbCtD
Temsirolimus—CYP2D6—Tamoxifen—breast cancer	0.00574	0.0169	CbGbCtD
Temsirolimus—CYP3A4—Raloxifene—breast cancer	0.00552	0.0162	CbGbCtD
Temsirolimus—CYP3A5—Docetaxel—breast cancer	0.00526	0.0155	CbGbCtD
Temsirolimus—ABCB1—Gemcitabine—breast cancer	0.00524	0.0154	CbGbCtD
Temsirolimus—ABCB1—Paclitaxel—breast cancer	0.00474	0.0139	CbGbCtD
Temsirolimus—ABCB1—Irinotecan—breast cancer	0.00467	0.0137	CbGbCtD
Temsirolimus—ABCB1—Vinblastine—breast cancer	0.00416	0.0122	CbGbCtD
Temsirolimus—CYP3A4—Vinorelbine—breast cancer	0.00404	0.0119	CbGbCtD
Temsirolimus—CYP2D6—Vinblastine—breast cancer	0.00392	0.0115	CbGbCtD
Temsirolimus—CYP3A4—Tamoxifen—breast cancer	0.00365	0.0107	CbGbCtD
Temsirolimus—CYP3A4—Mitoxantrone—breast cancer	0.00356	0.0105	CbGbCtD
Temsirolimus—ABCB1—Docetaxel—breast cancer	0.00343	0.0101	CbGbCtD
Temsirolimus—CYP3A4—Paclitaxel—breast cancer	0.00284	0.00835	CbGbCtD
Temsirolimus—CYP3A4—Irinotecan—breast cancer	0.0028	0.00823	CbGbCtD
Temsirolimus—ABCB1—Doxorubicin—breast cancer	0.00255	0.00751	CbGbCtD
Temsirolimus—CYP3A4—Vinblastine—breast cancer	0.00249	0.00732	CbGbCtD
Temsirolimus—ABCB1—Methotrexate—breast cancer	0.00247	0.00727	CbGbCtD
Temsirolimus—CYP2D6—Doxorubicin—breast cancer	0.00241	0.00707	CbGbCtD
Temsirolimus—CYP3A4—Docetaxel—breast cancer	0.00205	0.00603	CbGbCtD
Temsirolimus—MTOR—mammary gland—breast cancer	0.00154	0.0642	CbGeAlD
Temsirolimus—CYP3A4—Doxorubicin—breast cancer	0.00153	0.0045	CbGbCtD
Temsirolimus—FKBP1A—mammary gland—breast cancer	0.00139	0.0578	CbGeAlD
Temsirolimus—FKBP1A—nipple—breast cancer	0.00115	0.0478	CbGeAlD
Temsirolimus—MTOR—embryo—breast cancer	0.00105	0.0438	CbGeAlD
Temsirolimus—MTOR—epithelium—breast cancer	0.000858	0.0358	CbGeAlD
Temsirolimus—Everolimus—MTOR—breast cancer	0.000847	0.212	CrCbGaD
Temsirolimus—Pimecrolimus—MTOR—breast cancer	0.000847	0.212	CrCbGaD
Temsirolimus—MTOR—skin of body—breast cancer	0.000816	0.034	CbGeAlD
Temsirolimus—FKBP1A—epithelium—breast cancer	0.000772	0.0322	CbGeAlD
Temsirolimus—MTOR—endometrium—breast cancer	0.00077	0.0321	CbGeAlD
Temsirolimus—FKBP1A—skin of body—breast cancer	0.000734	0.0306	CbGeAlD
Temsirolimus—MTOR—uterus—breast cancer	0.000709	0.0296	CbGeAlD
Temsirolimus—MTOR—pituitary gland—breast cancer	0.000696	0.029	CbGeAlD
Temsirolimus—MTOR—adipose tissue—breast cancer	0.000694	0.0289	CbGeAlD
Temsirolimus—FKBP1A—endometrium—breast cancer	0.000692	0.0289	CbGeAlD
Temsirolimus—FKBP1A—uterus—breast cancer	0.000638	0.0266	CbGeAlD
Temsirolimus—MTOR—female reproductive system—breast cancer	0.000638	0.0266	CbGeAlD
Temsirolimus—FKBP1A—pituitary gland—breast cancer	0.000626	0.0261	CbGeAlD
Temsirolimus—FKBP1A—adipose tissue—breast cancer	0.000624	0.026	CbGeAlD
Temsirolimus—MTOR—adrenal gland—breast cancer	0.000622	0.0259	CbGeAlD
Temsirolimus—MTOR—bone marrow—breast cancer	0.000602	0.0251	CbGeAlD
Temsirolimus—CYP3A7—endocrine gland—breast cancer	0.0006	0.025	CbGeAlD
Temsirolimus—MTOR—female gonad—breast cancer	0.00058	0.0242	CbGeAlD
Temsirolimus—FKBP1A—female reproductive system—breast cancer	0.000573	0.0239	CbGeAlD
Temsirolimus—FKBP1A—adrenal gland—breast cancer	0.00056	0.0233	CbGeAlD
Temsirolimus—FKBP1A—bone marrow—breast cancer	0.000541	0.0226	CbGeAlD
Temsirolimus—MTOR—endocrine gland—breast cancer	0.00054	0.0225	CbGeAlD
Temsirolimus—FKBP1A—female gonad—breast cancer	0.000522	0.0218	CbGeAlD
Temsirolimus—Tacrolimus—MTOR—breast cancer	0.000504	0.126	CrCbGaD
Temsirolimus—Sirolimus—MTOR—breast cancer	0.000504	0.126	CrCbGaD
Temsirolimus—FKBP1A—endocrine gland—breast cancer	0.000485	0.0202	CbGeAlD
Temsirolimus—Sirolimus—SLCO1B1—breast cancer	0.000478	0.119	CrCbGaD
Temsirolimus—MTOR—lymph node—breast cancer	0.000373	0.0155	CbGeAlD
Temsirolimus—FKBP1A—lymph node—breast cancer	0.000335	0.014	CbGeAlD
Temsirolimus—CYP3A5—adipose tissue—breast cancer	0.000272	0.0113	CbGeAlD
Temsirolimus—CYP3A5—female gonad—breast cancer	0.000227	0.00947	CbGeAlD
Temsirolimus—ABCB1—embryo—breast cancer	0.000219	0.00912	CbGeAlD
Temsirolimus—CYP3A5—endocrine gland—breast cancer	0.000211	0.00881	CbGeAlD
Temsirolimus—CYP3A4—female reproductive system—breast cancer	0.000187	0.00781	CbGeAlD
Temsirolimus—CYP2D6—female reproductive system—breast cancer	0.000184	0.00769	CbGeAlD
Temsirolimus—ABCB1—epithelium—breast cancer	0.000179	0.00744	CbGeAlD
Temsirolimus—Everolimus—CYP3A4—breast cancer	0.000175	0.0437	CrCbGaD
Temsirolimus—Pimecrolimus—CYP3A4—breast cancer	0.000175	0.0437	CrCbGaD
Temsirolimus—CYP2D6—female gonad—breast cancer	0.000168	0.007	CbGeAlD
Temsirolimus—ABCB1—endometrium—breast cancer	0.00016	0.00668	CbGeAlD
Temsirolimus—CYP3A4—endocrine gland—breast cancer	0.000159	0.00661	CbGeAlD
Temsirolimus—CYP2D6—endocrine gland—breast cancer	0.000156	0.00651	CbGeAlD
Temsirolimus—ABCB1—uterus—breast cancer	0.000148	0.00615	CbGeAlD
Temsirolimus—ABCB1—pituitary gland—breast cancer	0.000145	0.00604	CbGeAlD
Temsirolimus—ABCB1—adipose tissue—breast cancer	0.000144	0.00602	CbGeAlD
Temsirolimus—ABCB1—female reproductive system—breast cancer	0.000133	0.00553	CbGeAlD
Temsirolimus—ABCB1—adrenal gland—breast cancer	0.000129	0.0054	CbGeAlD
Temsirolimus—ABCB1—bone marrow—breast cancer	0.000125	0.00522	CbGeAlD
Temsirolimus—ABCB1—female gonad—breast cancer	0.000121	0.00503	CbGeAlD
Temsirolimus—ABCB1—endocrine gland—breast cancer	0.000112	0.00468	CbGeAlD
Temsirolimus—Sirolimus—CYP3A4—breast cancer	0.000104	0.026	CrCbGaD
Temsirolimus—Tacrolimus—CYP3A4—breast cancer	0.000104	0.026	CrCbGaD
Temsirolimus—Tacrolimus—ALB—breast cancer	9.07e-05	0.0227	CrCbGaD
Temsirolimus—Sirolimus—ABCB1—breast cancer	8.66e-05	0.0216	CrCbGaD
Temsirolimus—Tacrolimus—ABCB1—breast cancer	8.66e-05	0.0216	CrCbGaD
Temsirolimus—ABCB1—lymph node—breast cancer	7.76e-05	0.00324	CbGeAlD
Temsirolimus—Erythema multiforme—Methotrexate—breast cancer	2.49e-05	0.000164	CcSEcCtD
Temsirolimus—Dizziness—Irinotecan—breast cancer	2.49e-05	0.000163	CcSEcCtD
Temsirolimus—Stomatitis—Doxorubicin—breast cancer	2.48e-05	0.000163	CcSEcCtD
Temsirolimus—Anorexia—Docetaxel—breast cancer	2.48e-05	0.000163	CcSEcCtD
Temsirolimus—Rhinitis—Epirubicin—breast cancer	2.47e-05	0.000162	CcSEcCtD
Temsirolimus—Urinary tract infection—Doxorubicin—breast cancer	2.47e-05	0.000162	CcSEcCtD
Temsirolimus—Conjunctivitis—Doxorubicin—breast cancer	2.47e-05	0.000162	CcSEcCtD
Temsirolimus—Nervous system disorder—Capecitabine—breast cancer	2.47e-05	0.000162	CcSEcCtD
Temsirolimus—Eye disorder—Methotrexate—breast cancer	2.46e-05	0.000162	CcSEcCtD
Temsirolimus—Diarrhoea—Fluorouracil—breast cancer	2.46e-05	0.000162	CcSEcCtD
Temsirolimus—Thrombocytopenia—Capecitabine—breast cancer	2.46e-05	0.000162	CcSEcCtD
Temsirolimus—Pharyngitis—Epirubicin—breast cancer	2.45e-05	0.000161	CcSEcCtD
Temsirolimus—Cardiac disorder—Methotrexate—breast cancer	2.45e-05	0.000161	CcSEcCtD
Temsirolimus—Skin disorder—Capecitabine—breast cancer	2.44e-05	0.000161	CcSEcCtD
Temsirolimus—Urinary tract disorder—Epirubicin—breast cancer	2.44e-05	0.00016	CcSEcCtD
Temsirolimus—Oedema peripheral—Epirubicin—breast cancer	2.43e-05	0.00016	CcSEcCtD
Temsirolimus—Haematuria—Doxorubicin—breast cancer	2.42e-05	0.000159	CcSEcCtD
Temsirolimus—Connective tissue disorder—Epirubicin—breast cancer	2.42e-05	0.000159	CcSEcCtD
Temsirolimus—Abdominal pain—Paclitaxel—breast cancer	2.42e-05	0.000159	CcSEcCtD
Temsirolimus—Body temperature increased—Paclitaxel—breast cancer	2.42e-05	0.000159	CcSEcCtD
Temsirolimus—Urethral disorder—Epirubicin—breast cancer	2.42e-05	0.000159	CcSEcCtD
Temsirolimus—Epistaxis—Doxorubicin—breast cancer	2.4e-05	0.000158	CcSEcCtD
Temsirolimus—Anorexia—Capecitabine—breast cancer	2.4e-05	0.000158	CcSEcCtD
Temsirolimus—Angiopathy—Methotrexate—breast cancer	2.39e-05	0.000157	CcSEcCtD
Temsirolimus—Vomiting—Mitoxantrone—breast cancer	2.39e-05	0.000157	CcSEcCtD
Temsirolimus—Vomiting—Irinotecan—breast cancer	2.39e-05	0.000157	CcSEcCtD
Temsirolimus—Sinusitis—Doxorubicin—breast cancer	2.39e-05	0.000157	CcSEcCtD
Temsirolimus—Immune system disorder—Methotrexate—breast cancer	2.38e-05	0.000156	CcSEcCtD
Temsirolimus—Dizziness—Fluorouracil—breast cancer	2.38e-05	0.000156	CcSEcCtD
Temsirolimus—Mediastinal disorder—Methotrexate—breast cancer	2.38e-05	0.000156	CcSEcCtD
Temsirolimus—Rash—Mitoxantrone—breast cancer	2.37e-05	0.000156	CcSEcCtD
Temsirolimus—Rash—Irinotecan—breast cancer	2.37e-05	0.000156	CcSEcCtD
Temsirolimus—Dermatitis—Mitoxantrone—breast cancer	2.37e-05	0.000156	CcSEcCtD
Temsirolimus—Dermatitis—Irinotecan—breast cancer	2.37e-05	0.000156	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Docetaxel—breast cancer	2.37e-05	0.000156	CcSEcCtD
Temsirolimus—Chills—Methotrexate—breast cancer	2.37e-05	0.000155	CcSEcCtD
Temsirolimus—Headache—Mitoxantrone—breast cancer	2.35e-05	0.000155	CcSEcCtD
Temsirolimus—Headache—Irinotecan—breast cancer	2.35e-05	0.000155	CcSEcCtD
Temsirolimus—Insomnia—Docetaxel—breast cancer	2.35e-05	0.000154	CcSEcCtD
Temsirolimus—Erythema multiforme—Epirubicin—breast cancer	2.33e-05	0.000153	CcSEcCtD
Temsirolimus—Vomiting—Gemcitabine—breast cancer	2.33e-05	0.000153	CcSEcCtD
Temsirolimus—Dyspnoea—Docetaxel—breast cancer	2.32e-05	0.000152	CcSEcCtD
Temsirolimus—Somnolence—Docetaxel—breast cancer	2.31e-05	0.000152	CcSEcCtD
Temsirolimus—Mental disorder—Methotrexate—breast cancer	2.31e-05	0.000152	CcSEcCtD
Temsirolimus—Rash—Gemcitabine—breast cancer	2.31e-05	0.000152	CcSEcCtD
Temsirolimus—Dermatitis—Gemcitabine—breast cancer	2.31e-05	0.000152	CcSEcCtD
Temsirolimus—Eye disorder—Epirubicin—breast cancer	2.31e-05	0.000151	CcSEcCtD
Temsirolimus—Erythema—Methotrexate—breast cancer	2.29e-05	0.000151	CcSEcCtD
Temsirolimus—Malnutrition—Methotrexate—breast cancer	2.29e-05	0.000151	CcSEcCtD
Temsirolimus—Headache—Gemcitabine—breast cancer	2.29e-05	0.000151	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Capecitabine—breast cancer	2.29e-05	0.000151	CcSEcCtD
Temsirolimus—Cardiac disorder—Epirubicin—breast cancer	2.29e-05	0.00015	CcSEcCtD
Temsirolimus—Vomiting—Fluorouracil—breast cancer	2.29e-05	0.00015	CcSEcCtD
Temsirolimus—Rhinitis—Doxorubicin—breast cancer	2.29e-05	0.00015	CcSEcCtD
Temsirolimus—Insomnia—Capecitabine—breast cancer	2.28e-05	0.000149	CcSEcCtD
Temsirolimus—Rash—Fluorouracil—breast cancer	2.27e-05	0.000149	CcSEcCtD
Temsirolimus—Dermatitis—Fluorouracil—breast cancer	2.27e-05	0.000149	CcSEcCtD
Temsirolimus—Pharyngitis—Doxorubicin—breast cancer	2.27e-05	0.000149	CcSEcCtD
Temsirolimus—Decreased appetite—Docetaxel—breast cancer	2.26e-05	0.000148	CcSEcCtD
Temsirolimus—Hypersensitivity—Paclitaxel—breast cancer	2.26e-05	0.000148	CcSEcCtD
Temsirolimus—Headache—Fluorouracil—breast cancer	2.26e-05	0.000148	CcSEcCtD
Temsirolimus—Urinary tract disorder—Doxorubicin—breast cancer	2.25e-05	0.000148	CcSEcCtD
Temsirolimus—Oedema peripheral—Doxorubicin—breast cancer	2.25e-05	0.000148	CcSEcCtD
Temsirolimus—Dysgeusia—Methotrexate—breast cancer	2.25e-05	0.000148	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Docetaxel—breast cancer	2.24e-05	0.000147	CcSEcCtD
Temsirolimus—Connective tissue disorder—Doxorubicin—breast cancer	2.24e-05	0.000147	CcSEcCtD
Temsirolimus—Dyspnoea—Capecitabine—breast cancer	2.24e-05	0.000147	CcSEcCtD
Temsirolimus—Fatigue—Docetaxel—breast cancer	2.24e-05	0.000147	CcSEcCtD
Temsirolimus—Angiopathy—Epirubicin—breast cancer	2.24e-05	0.000147	CcSEcCtD
Temsirolimus—Urethral disorder—Doxorubicin—breast cancer	2.24e-05	0.000147	CcSEcCtD
Temsirolimus—Nausea—Mitoxantrone—breast cancer	2.23e-05	0.000147	CcSEcCtD
Temsirolimus—Nausea—Irinotecan—breast cancer	2.23e-05	0.000147	CcSEcCtD
Temsirolimus—Immune system disorder—Epirubicin—breast cancer	2.23e-05	0.000146	CcSEcCtD
Temsirolimus—Mediastinal disorder—Epirubicin—breast cancer	2.22e-05	0.000146	CcSEcCtD
Temsirolimus—Constipation—Docetaxel—breast cancer	2.22e-05	0.000146	CcSEcCtD
Temsirolimus—Pain—Docetaxel—breast cancer	2.22e-05	0.000146	CcSEcCtD
Temsirolimus—Back pain—Methotrexate—breast cancer	2.22e-05	0.000146	CcSEcCtD
Temsirolimus—Chills—Epirubicin—breast cancer	2.21e-05	0.000145	CcSEcCtD
Temsirolimus—Asthenia—Paclitaxel—breast cancer	2.2e-05	0.000144	CcSEcCtD
Temsirolimus—Decreased appetite—Capecitabine—breast cancer	2.19e-05	0.000144	CcSEcCtD
Temsirolimus—Nausea—Gemcitabine—breast cancer	2.17e-05	0.000143	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Capecitabine—breast cancer	2.17e-05	0.000143	CcSEcCtD
Temsirolimus—Fatigue—Capecitabine—breast cancer	2.17e-05	0.000142	CcSEcCtD
Temsirolimus—Pruritus—Paclitaxel—breast cancer	2.17e-05	0.000142	CcSEcCtD
Temsirolimus—Mental disorder—Epirubicin—breast cancer	2.16e-05	0.000142	CcSEcCtD
Temsirolimus—Erythema multiforme—Doxorubicin—breast cancer	2.16e-05	0.000142	CcSEcCtD
Temsirolimus—Pain—Capecitabine—breast cancer	2.15e-05	0.000141	CcSEcCtD
Temsirolimus—Constipation—Capecitabine—breast cancer	2.15e-05	0.000141	CcSEcCtD
Temsirolimus—Malnutrition—Epirubicin—breast cancer	2.15e-05	0.000141	CcSEcCtD
Temsirolimus—Erythema—Epirubicin—breast cancer	2.15e-05	0.000141	CcSEcCtD
Temsirolimus—Nausea—Fluorouracil—breast cancer	2.14e-05	0.00014	CcSEcCtD
Temsirolimus—Eye disorder—Doxorubicin—breast cancer	2.13e-05	0.00014	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Docetaxel—breast cancer	2.12e-05	0.00014	CcSEcCtD
Temsirolimus—Anaemia—Methotrexate—breast cancer	2.12e-05	0.000139	CcSEcCtD
Temsirolimus—Cardiac disorder—Doxorubicin—breast cancer	2.12e-05	0.000139	CcSEcCtD
Temsirolimus—Dysgeusia—Epirubicin—breast cancer	2.1e-05	0.000138	CcSEcCtD
Temsirolimus—Diarrhoea—Paclitaxel—breast cancer	2.1e-05	0.000138	CcSEcCtD
Temsirolimus—Back pain—Epirubicin—breast cancer	2.08e-05	0.000136	CcSEcCtD
Temsirolimus—Angiopathy—Doxorubicin—breast cancer	2.07e-05	0.000136	CcSEcCtD
Temsirolimus—Immune system disorder—Doxorubicin—breast cancer	2.06e-05	0.000135	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Capecitabine—breast cancer	2.06e-05	0.000135	CcSEcCtD
Temsirolimus—Mediastinal disorder—Doxorubicin—breast cancer	2.06e-05	0.000135	CcSEcCtD
Temsirolimus—Body temperature increased—Docetaxel—breast cancer	2.05e-05	0.000135	CcSEcCtD
Temsirolimus—Abdominal pain—Docetaxel—breast cancer	2.05e-05	0.000135	CcSEcCtD
Temsirolimus—Leukopenia—Methotrexate—breast cancer	2.05e-05	0.000135	CcSEcCtD
Temsirolimus—Chills—Doxorubicin—breast cancer	2.05e-05	0.000135	CcSEcCtD
Temsirolimus—Dizziness—Paclitaxel—breast cancer	2.03e-05	0.000133	CcSEcCtD
Temsirolimus—Cough—Methotrexate—breast cancer	2e-05	0.000132	CcSEcCtD
Temsirolimus—Mental disorder—Doxorubicin—breast cancer	2e-05	0.000131	CcSEcCtD
Temsirolimus—Abdominal pain—Capecitabine—breast cancer	1.99e-05	0.000131	CcSEcCtD
Temsirolimus—Body temperature increased—Capecitabine—breast cancer	1.99e-05	0.000131	CcSEcCtD
Temsirolimus—Convulsion—Methotrexate—breast cancer	1.99e-05	0.000131	CcSEcCtD
Temsirolimus—Malnutrition—Doxorubicin—breast cancer	1.99e-05	0.000131	CcSEcCtD
Temsirolimus—Erythema—Doxorubicin—breast cancer	1.99e-05	0.000131	CcSEcCtD
Temsirolimus—Anaemia—Epirubicin—breast cancer	1.98e-05	0.00013	CcSEcCtD
Temsirolimus—Myalgia—Methotrexate—breast cancer	1.95e-05	0.000128	CcSEcCtD
Temsirolimus—Arthralgia—Methotrexate—breast cancer	1.95e-05	0.000128	CcSEcCtD
Temsirolimus—Chest pain—Methotrexate—breast cancer	1.95e-05	0.000128	CcSEcCtD
Temsirolimus—Vomiting—Paclitaxel—breast cancer	1.95e-05	0.000128	CcSEcCtD
Temsirolimus—Dysgeusia—Doxorubicin—breast cancer	1.95e-05	0.000128	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.94e-05	0.000127	CcSEcCtD
Temsirolimus—Rash—Paclitaxel—breast cancer	1.93e-05	0.000127	CcSEcCtD
Temsirolimus—Dermatitis—Paclitaxel—breast cancer	1.93e-05	0.000127	CcSEcCtD
Temsirolimus—Leukopenia—Epirubicin—breast cancer	1.92e-05	0.000126	CcSEcCtD
Temsirolimus—Back pain—Doxorubicin—breast cancer	1.92e-05	0.000126	CcSEcCtD
Temsirolimus—Headache—Paclitaxel—breast cancer	1.92e-05	0.000126	CcSEcCtD
Temsirolimus—Hypersensitivity—Docetaxel—breast cancer	1.91e-05	0.000126	CcSEcCtD
Temsirolimus—Cough—Epirubicin—breast cancer	1.87e-05	0.000123	CcSEcCtD
Temsirolimus—Anaphylactic shock—Methotrexate—breast cancer	1.87e-05	0.000123	CcSEcCtD
Temsirolimus—Asthenia—Docetaxel—breast cancer	1.86e-05	0.000122	CcSEcCtD
Temsirolimus—Convulsion—Epirubicin—breast cancer	1.86e-05	0.000122	CcSEcCtD
Temsirolimus—Infection—Methotrexate—breast cancer	1.86e-05	0.000122	CcSEcCtD
Temsirolimus—Hypertension—Epirubicin—breast cancer	1.85e-05	0.000122	CcSEcCtD
Temsirolimus—Hypersensitivity—Capecitabine—breast cancer	1.85e-05	0.000122	CcSEcCtD
Temsirolimus—Pruritus—Docetaxel—breast cancer	1.84e-05	0.000121	CcSEcCtD
Temsirolimus—Nervous system disorder—Methotrexate—breast cancer	1.84e-05	0.000121	CcSEcCtD
Temsirolimus—Anaemia—Doxorubicin—breast cancer	1.84e-05	0.000121	CcSEcCtD
Temsirolimus—Thrombocytopenia—Methotrexate—breast cancer	1.83e-05	0.00012	CcSEcCtD
Temsirolimus—Chest pain—Epirubicin—breast cancer	1.83e-05	0.00012	CcSEcCtD
Temsirolimus—Myalgia—Epirubicin—breast cancer	1.83e-05	0.00012	CcSEcCtD
Temsirolimus—Arthralgia—Epirubicin—breast cancer	1.83e-05	0.00012	CcSEcCtD
Temsirolimus—Anxiety—Epirubicin—breast cancer	1.82e-05	0.00012	CcSEcCtD
Temsirolimus—Nausea—Paclitaxel—breast cancer	1.82e-05	0.00012	CcSEcCtD
Temsirolimus—Skin disorder—Methotrexate—breast cancer	1.82e-05	0.000119	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.82e-05	0.000119	CcSEcCtD
Temsirolimus—Asthenia—Capecitabine—breast cancer	1.8e-05	0.000119	CcSEcCtD
Temsirolimus—Anorexia—Methotrexate—breast cancer	1.79e-05	0.000117	CcSEcCtD
Temsirolimus—Pruritus—Capecitabine—breast cancer	1.78e-05	0.000117	CcSEcCtD
Temsirolimus—Leukopenia—Doxorubicin—breast cancer	1.78e-05	0.000117	CcSEcCtD
Temsirolimus—Diarrhoea—Docetaxel—breast cancer	1.78e-05	0.000117	CcSEcCtD
Temsirolimus—Oedema—Epirubicin—breast cancer	1.75e-05	0.000115	CcSEcCtD
Temsirolimus—Anaphylactic shock—Epirubicin—breast cancer	1.75e-05	0.000115	CcSEcCtD
Temsirolimus—Infection—Epirubicin—breast cancer	1.74e-05	0.000114	CcSEcCtD
Temsirolimus—Cough—Doxorubicin—breast cancer	1.73e-05	0.000114	CcSEcCtD
Temsirolimus—Convulsion—Doxorubicin—breast cancer	1.72e-05	0.000113	CcSEcCtD
Temsirolimus—Diarrhoea—Capecitabine—breast cancer	1.72e-05	0.000113	CcSEcCtD
Temsirolimus—Nervous system disorder—Epirubicin—breast cancer	1.72e-05	0.000113	CcSEcCtD
Temsirolimus—Dizziness—Docetaxel—breast cancer	1.72e-05	0.000113	CcSEcCtD
Temsirolimus—Thrombocytopenia—Epirubicin—breast cancer	1.72e-05	0.000113	CcSEcCtD
Temsirolimus—Hypertension—Doxorubicin—breast cancer	1.72e-05	0.000113	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Methotrexate—breast cancer	1.71e-05	0.000112	CcSEcCtD
Temsirolimus—Skin disorder—Epirubicin—breast cancer	1.7e-05	0.000112	CcSEcCtD
Temsirolimus—Insomnia—Methotrexate—breast cancer	1.69e-05	0.000111	CcSEcCtD
Temsirolimus—Myalgia—Doxorubicin—breast cancer	1.69e-05	0.000111	CcSEcCtD
Temsirolimus—Arthralgia—Doxorubicin—breast cancer	1.69e-05	0.000111	CcSEcCtD
Temsirolimus—Chest pain—Doxorubicin—breast cancer	1.69e-05	0.000111	CcSEcCtD
Temsirolimus—Anxiety—Doxorubicin—breast cancer	1.69e-05	0.000111	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.68e-05	0.00011	CcSEcCtD
Temsirolimus—Anorexia—Epirubicin—breast cancer	1.67e-05	0.00011	CcSEcCtD
Temsirolimus—Dyspnoea—Methotrexate—breast cancer	1.67e-05	0.00011	CcSEcCtD
Temsirolimus—Somnolence—Methotrexate—breast cancer	1.66e-05	0.000109	CcSEcCtD
Temsirolimus—Dizziness—Capecitabine—breast cancer	1.66e-05	0.000109	CcSEcCtD
Temsirolimus—Vomiting—Docetaxel—breast cancer	1.65e-05	0.000109	CcSEcCtD
Temsirolimus—Rash—Docetaxel—breast cancer	1.64e-05	0.000108	CcSEcCtD
Temsirolimus—Dermatitis—Docetaxel—breast cancer	1.64e-05	0.000108	CcSEcCtD
Temsirolimus—Decreased appetite—Methotrexate—breast cancer	1.63e-05	0.000107	CcSEcCtD
Temsirolimus—Headache—Docetaxel—breast cancer	1.63e-05	0.000107	CcSEcCtD
Temsirolimus—Oedema—Doxorubicin—breast cancer	1.62e-05	0.000107	CcSEcCtD
Temsirolimus—Anaphylactic shock—Doxorubicin—breast cancer	1.62e-05	0.000107	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Methotrexate—breast cancer	1.62e-05	0.000106	CcSEcCtD
Temsirolimus—Fatigue—Methotrexate—breast cancer	1.61e-05	0.000106	CcSEcCtD
Temsirolimus—Infection—Doxorubicin—breast cancer	1.61e-05	0.000106	CcSEcCtD
Temsirolimus—Pain—Methotrexate—breast cancer	1.6e-05	0.000105	CcSEcCtD
Temsirolimus—Vomiting—Capecitabine—breast cancer	1.6e-05	0.000105	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Epirubicin—breast cancer	1.6e-05	0.000105	CcSEcCtD
Temsirolimus—Nervous system disorder—Doxorubicin—breast cancer	1.59e-05	0.000104	CcSEcCtD
Temsirolimus—Thrombocytopenia—Doxorubicin—breast cancer	1.59e-05	0.000104	CcSEcCtD
Temsirolimus—Rash—Capecitabine—breast cancer	1.59e-05	0.000104	CcSEcCtD
Temsirolimus—Insomnia—Epirubicin—breast cancer	1.59e-05	0.000104	CcSEcCtD
Temsirolimus—Dermatitis—Capecitabine—breast cancer	1.58e-05	0.000104	CcSEcCtD
Temsirolimus—Headache—Capecitabine—breast cancer	1.58e-05	0.000104	CcSEcCtD
Temsirolimus—Skin disorder—Doxorubicin—breast cancer	1.58e-05	0.000103	CcSEcCtD
Temsirolimus—Dyspnoea—Epirubicin—breast cancer	1.56e-05	0.000103	CcSEcCtD
Temsirolimus—Somnolence—Epirubicin—breast cancer	1.56e-05	0.000102	CcSEcCtD
Temsirolimus—Anorexia—Doxorubicin—breast cancer	1.55e-05	0.000102	CcSEcCtD
Temsirolimus—Nausea—Docetaxel—breast cancer	1.54e-05	0.000101	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Methotrexate—breast cancer	1.53e-05	0.000101	CcSEcCtD
Temsirolimus—Decreased appetite—Epirubicin—breast cancer	1.52e-05	0.0001	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Epirubicin—breast cancer	1.51e-05	9.94e-05	CcSEcCtD
Temsirolimus—Fatigue—Epirubicin—breast cancer	1.51e-05	9.93e-05	CcSEcCtD
Temsirolimus—Constipation—Epirubicin—breast cancer	1.5e-05	9.84e-05	CcSEcCtD
Temsirolimus—Pain—Epirubicin—breast cancer	1.5e-05	9.84e-05	CcSEcCtD
Temsirolimus—Nausea—Capecitabine—breast cancer	1.49e-05	9.82e-05	CcSEcCtD
Temsirolimus—Abdominal pain—Methotrexate—breast cancer	1.48e-05	9.72e-05	CcSEcCtD
Temsirolimus—Body temperature increased—Methotrexate—breast cancer	1.48e-05	9.72e-05	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Doxorubicin—breast cancer	1.48e-05	9.71e-05	CcSEcCtD
Temsirolimus—Insomnia—Doxorubicin—breast cancer	1.47e-05	9.63e-05	CcSEcCtD
Temsirolimus—Dyspnoea—Doxorubicin—breast cancer	1.45e-05	9.5e-05	CcSEcCtD
Temsirolimus—Somnolence—Doxorubicin—breast cancer	1.44e-05	9.47e-05	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Epirubicin—breast cancer	1.43e-05	9.41e-05	CcSEcCtD
Temsirolimus—Decreased appetite—Doxorubicin—breast cancer	1.41e-05	9.26e-05	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Doxorubicin—breast cancer	1.4e-05	9.2e-05	CcSEcCtD
Temsirolimus—Fatigue—Doxorubicin—breast cancer	1.4e-05	9.18e-05	CcSEcCtD
Temsirolimus—Pain—Doxorubicin—breast cancer	1.39e-05	9.11e-05	CcSEcCtD
Temsirolimus—Constipation—Doxorubicin—breast cancer	1.39e-05	9.11e-05	CcSEcCtD
Temsirolimus—Abdominal pain—Epirubicin—breast cancer	1.39e-05	9.1e-05	CcSEcCtD
Temsirolimus—Body temperature increased—Epirubicin—breast cancer	1.39e-05	9.1e-05	CcSEcCtD
Temsirolimus—Hypersensitivity—Methotrexate—breast cancer	1.38e-05	9.06e-05	CcSEcCtD
Temsirolimus—Asthenia—Methotrexate—breast cancer	1.34e-05	8.83e-05	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Doxorubicin—breast cancer	1.33e-05	8.71e-05	CcSEcCtD
Temsirolimus—Pruritus—Methotrexate—breast cancer	1.32e-05	8.7e-05	CcSEcCtD
Temsirolimus—Hypersensitivity—Epirubicin—breast cancer	1.29e-05	8.48e-05	CcSEcCtD
Temsirolimus—Abdominal pain—Doxorubicin—breast cancer	1.28e-05	8.42e-05	CcSEcCtD
Temsirolimus—Body temperature increased—Doxorubicin—breast cancer	1.28e-05	8.42e-05	CcSEcCtD
Temsirolimus—Diarrhoea—Methotrexate—breast cancer	1.28e-05	8.42e-05	CcSEcCtD
Temsirolimus—Asthenia—Epirubicin—breast cancer	1.26e-05	8.26e-05	CcSEcCtD
Temsirolimus—Pruritus—Epirubicin—breast cancer	1.24e-05	8.15e-05	CcSEcCtD
Temsirolimus—Dizziness—Methotrexate—breast cancer	1.24e-05	8.14e-05	CcSEcCtD
Temsirolimus—Diarrhoea—Epirubicin—breast cancer	1.2e-05	7.88e-05	CcSEcCtD
Temsirolimus—Hypersensitivity—Doxorubicin—breast cancer	1.19e-05	7.85e-05	CcSEcCtD
Temsirolimus—Vomiting—Methotrexate—breast cancer	1.19e-05	7.82e-05	CcSEcCtD
Temsirolimus—Rash—Methotrexate—breast cancer	1.18e-05	7.76e-05	CcSEcCtD
Temsirolimus—Dermatitis—Methotrexate—breast cancer	1.18e-05	7.75e-05	CcSEcCtD
Temsirolimus—Headache—Methotrexate—breast cancer	1.17e-05	7.71e-05	CcSEcCtD
Temsirolimus—Asthenia—Doxorubicin—breast cancer	1.16e-05	7.64e-05	CcSEcCtD
Temsirolimus—Dizziness—Epirubicin—breast cancer	1.16e-05	7.61e-05	CcSEcCtD
Temsirolimus—Pruritus—Doxorubicin—breast cancer	1.15e-05	7.54e-05	CcSEcCtD
Temsirolimus—Vomiting—Epirubicin—breast cancer	1.11e-05	7.32e-05	CcSEcCtD
Temsirolimus—Nausea—Methotrexate—breast cancer	1.11e-05	7.31e-05	CcSEcCtD
Temsirolimus—Diarrhoea—Doxorubicin—breast cancer	1.11e-05	7.29e-05	CcSEcCtD
Temsirolimus—Rash—Epirubicin—breast cancer	1.11e-05	7.26e-05	CcSEcCtD
Temsirolimus—Dermatitis—Epirubicin—breast cancer	1.1e-05	7.25e-05	CcSEcCtD
Temsirolimus—Headache—Epirubicin—breast cancer	1.1e-05	7.21e-05	CcSEcCtD
Temsirolimus—Dizziness—Doxorubicin—breast cancer	1.07e-05	7.04e-05	CcSEcCtD
Temsirolimus—Nausea—Epirubicin—breast cancer	1.04e-05	6.84e-05	CcSEcCtD
Temsirolimus—Vomiting—Doxorubicin—breast cancer	1.03e-05	6.77e-05	CcSEcCtD
Temsirolimus—Rash—Doxorubicin—breast cancer	1.02e-05	6.72e-05	CcSEcCtD
Temsirolimus—Dermatitis—Doxorubicin—breast cancer	1.02e-05	6.71e-05	CcSEcCtD
Temsirolimus—Headache—Doxorubicin—breast cancer	1.02e-05	6.67e-05	CcSEcCtD
Temsirolimus—Nausea—Doxorubicin—breast cancer	9.63e-06	6.33e-05	CcSEcCtD
Temsirolimus—MTOR—Immune System—PTEN—breast cancer	2.76e-06	2.83e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NOTCH1—breast cancer	2.75e-06	2.82e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTGS1—breast cancer	2.75e-06	2.82e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ENO1—breast cancer	2.75e-06	2.82e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—HMMR—breast cancer	2.74e-06	2.81e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ABCC1—breast cancer	2.74e-06	2.81e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTA3—breast cancer	2.74e-06	2.81e-05	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—AKT1—breast cancer	2.73e-06	2.8e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MAPK3—breast cancer	2.71e-06	2.78e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—COMT—breast cancer	2.71e-06	2.77e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—MAPK8—breast cancer	2.7e-06	2.77e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CYP2D6—breast cancer	2.69e-06	2.76e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KIT—breast cancer	2.69e-06	2.76e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—APC—breast cancer	2.69e-06	2.76e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PIK3CG—breast cancer	2.69e-06	2.76e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GSTP1—breast cancer	2.69e-06	2.76e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—EGF—breast cancer	2.66e-06	2.73e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—HMOX1—breast cancer	2.66e-06	2.72e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PPARGC1B—breast cancer	2.65e-06	2.72e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ITPR1—breast cancer	2.65e-06	2.72e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—NCOA2—breast cancer	2.64e-06	2.71e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MYC—breast cancer	2.64e-06	2.7e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TGFB1—breast cancer	2.63e-06	2.69e-05	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—AKT1—breast cancer	2.62e-06	2.69e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYP17A1—breast cancer	2.62e-06	2.68e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CTNNB1—breast cancer	2.61e-06	2.68e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—AKT1—breast cancer	2.61e-06	2.67e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTGS1—breast cancer	2.59e-06	2.65e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ENO1—breast cancer	2.59e-06	2.65e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—EGFR—breast cancer	2.58e-06	2.64e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—ALB—breast cancer	2.57e-06	2.63e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—FASN—breast cancer	2.56e-06	2.63e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—SRC—breast cancer	2.56e-06	2.62e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—BCHE—breast cancer	2.55e-06	2.62e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CDKN1A—breast cancer	2.55e-06	2.62e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ABCB1—breast cancer	2.55e-06	2.61e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PTEN—breast cancer	2.55e-06	2.61e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PIK3CG—breast cancer	2.54e-06	2.61e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—BRAF—breast cancer	2.53e-06	2.59e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—SLC5A5—breast cancer	2.52e-06	2.59e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CA9—breast cancer	2.51e-06	2.57e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTA4—breast cancer	2.51e-06	2.57e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—TYMS—breast cancer	2.5e-06	2.57e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—NCOA2—breast cancer	2.49e-06	2.55e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PLA2G4A—breast cancer	2.47e-06	2.54e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GSTM1—breast cancer	2.47e-06	2.54e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—NCOR1—breast cancer	2.47e-06	2.54e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—STAT3—breast cancer	2.47e-06	2.53e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IGF1—breast cancer	2.47e-06	2.53e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—AKT2—breast cancer	2.46e-06	2.53e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GPX2—breast cancer	2.44e-06	2.5e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTA2—breast cancer	2.44e-06	2.5e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—NQO1—breast cancer	2.44e-06	2.5e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—SLC2A1—breast cancer	2.44e-06	2.5e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—KRAS—breast cancer	2.43e-06	2.5e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—FASN—breast cancer	2.42e-06	2.48e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GPX4—breast cancer	2.41e-06	2.47e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—SULT1A1—breast cancer	2.41e-06	2.47e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—BCHE—breast cancer	2.41e-06	2.47e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—SLC5A5—breast cancer	2.38e-06	2.44e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CYP3A4—breast cancer	2.38e-06	2.44e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GPX1—breast cancer	2.37e-06	2.43e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PIK3CD—breast cancer	2.37e-06	2.43e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—SRC—breast cancer	2.36e-06	2.42e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—MAPK3—breast cancer	2.36e-06	2.42e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—IDH1—breast cancer	2.36e-06	2.41e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTA1—breast cancer	2.36e-06	2.41e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CYP1A1—breast cancer	2.35e-06	2.4e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—SERPINE1—breast cancer	2.34e-06	2.4e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CYP1B1—breast cancer	2.34e-06	2.39e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NAT2—breast cancer	2.33e-06	2.39e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ERCC2—breast cancer	2.33e-06	2.38e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—RAF1—breast cancer	2.32e-06	2.38e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—SLC2A1—breast cancer	2.3e-06	2.35e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—NQO1—breast cancer	2.3e-06	2.35e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—HSP90AA1—breast cancer	2.29e-06	2.35e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—STAT3—breast cancer	2.28e-06	2.33e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—EGFR—breast cancer	2.24e-06	2.3e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYP3A4—breast cancer	2.24e-06	2.29e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PIK3CA—breast cancer	2.24e-06	2.29e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NOS3—breast cancer	2.24e-06	2.29e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PIK3CD—breast cancer	2.23e-06	2.29e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—NCOA1—breast cancer	2.23e-06	2.28e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—ALB—breast cancer	2.21e-06	2.26e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYP1B1—breast cancer	2.2e-06	2.26e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—STK11—breast cancer	2.2e-06	2.25e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CYP19A1—breast cancer	2.2e-06	2.25e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—MTHFR—breast cancer	2.19e-06	2.24e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MAPK3—breast cancer	2.18e-06	2.23e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TP53—breast cancer	2.16e-06	2.22e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—HSP90AA1—breast cancer	2.16e-06	2.21e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MDM2—breast cancer	2.12e-06	2.17e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—KRAS—breast cancer	2.12e-06	2.17e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MYC—breast cancer	2.12e-06	2.17e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—RAF1—breast cancer	2.11e-06	2.17e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—TGFB1—breast cancer	2.11e-06	2.16e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—NOS3—breast cancer	2.11e-06	2.16e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—RELA—breast cancer	2.1e-06	2.16e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—NCOA1—breast cancer	2.1e-06	2.15e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—ERBB2—breast cancer	2.09e-06	2.14e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—EGFR—breast cancer	2.07e-06	2.12e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYP19A1—breast cancer	2.07e-06	2.12e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—STK11—breast cancer	2.07e-06	2.12e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—HRAS—breast cancer	2.07e-06	2.12e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PIK3CB—breast cancer	2.06e-06	2.11e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—MED12—breast cancer	2.04e-06	2.09e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—DPYD—breast cancer	2.04e-06	2.09e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—COMT—breast cancer	2.04e-06	2.09e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GSTP1—breast cancer	2.03e-06	2.08e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CAV1—breast cancer	2.02e-06	2.07e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ALDOA—breast cancer	2.01e-06	2.06e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—HMOX1—breast cancer	2e-06	2.05e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ITPR1—breast cancer	2e-06	2.05e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CXCL8—breast cancer	1.98e-06	2.03e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—IL6—breast cancer	1.98e-06	2.03e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—KRAS—breast cancer	1.96e-06	2e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NCOA3—breast cancer	1.95e-06	2e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PIK3CB—breast cancer	1.95e-06	2e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PIK3CA—breast cancer	1.95e-06	1.99e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—SLC2A2—breast cancer	1.94e-06	1.99e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CDKN1B—breast cancer	1.94e-06	1.98e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PTGS2—breast cancer	1.93e-06	1.98e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—COMT—breast cancer	1.92e-06	1.97e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GSTP1—breast cancer	1.92e-06	1.96e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—MTR—breast cancer	1.9e-06	1.95e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ABCG2—breast cancer	1.9e-06	1.95e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CPT1A—breast cancer	1.9e-06	1.95e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CASP3—breast cancer	1.9e-06	1.95e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IL2—breast cancer	1.9e-06	1.94e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—TYMS—breast cancer	1.89e-06	1.94e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—HMOX1—breast cancer	1.89e-06	1.94e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ITPR1—breast cancer	1.88e-06	1.93e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—NCOR1—breast cancer	1.87e-06	1.91e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GSTM1—breast cancer	1.87e-06	1.91e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PLA2G4A—breast cancer	1.87e-06	1.91e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—HPGDS—breast cancer	1.86e-06	1.91e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—HBA1—breast cancer	1.85e-06	1.9e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CCND1—breast cancer	1.85e-06	1.89e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—JUN—breast cancer	1.84e-06	1.89e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PIK3CG—breast cancer	1.84e-06	1.88e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CTNNB1—breast cancer	1.83e-06	1.88e-05	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—AKT1—breast cancer	1.83e-06	1.87e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ABCB1—breast cancer	1.81e-06	1.86e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTT1—breast cancer	1.81e-06	1.85e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ACHE—breast cancer	1.81e-06	1.85e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—HRAS—breast cancer	1.8e-06	1.84e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PIK3CA—breast cancer	1.8e-06	1.84e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MMP9—breast cancer	1.79e-06	1.84e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GPX1—breast cancer	1.79e-06	1.83e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CDKN1A—breast cancer	1.79e-06	1.83e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PTEN—breast cancer	1.78e-06	1.83e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—TYMS—breast cancer	1.78e-06	1.82e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CYP1A1—breast cancer	1.77e-06	1.81e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PLA2G4A—breast cancer	1.76e-06	1.8e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—NCOR1—breast cancer	1.76e-06	1.8e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GSTM1—breast cancer	1.76e-06	1.8e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ERCC2—breast cancer	1.76e-06	1.8e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MAPK8—breast cancer	1.74e-06	1.79e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—IL6—breast cancer	1.72e-06	1.77e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYP17A1—breast cancer	1.71e-06	1.75e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTGS1—breast cancer	1.69e-06	1.73e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ENO1—breast cancer	1.69e-06	1.73e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GPX1—breast cancer	1.69e-06	1.73e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PTEN—breast cancer	1.68e-06	1.73e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYP1A1—breast cancer	1.67e-06	1.71e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—HRAS—breast cancer	1.66e-06	1.7e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYP2D6—breast cancer	1.66e-06	1.7e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ERCC2—breast cancer	1.65e-06	1.7e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—SRC—breast cancer	1.65e-06	1.69e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—MTHFR—breast cancer	1.65e-06	1.69e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NCOA2—breast cancer	1.63e-06	1.67e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PIK3CD—breast cancer	1.62e-06	1.66e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—VEGFA—breast cancer	1.61e-06	1.65e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—STAT3—breast cancer	1.59e-06	1.63e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ALB—breast cancer	1.59e-06	1.63e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—IL6—breast cancer	1.59e-06	1.63e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—AKT1—breast cancer	1.59e-06	1.63e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—FASN—breast cancer	1.58e-06	1.62e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—BCHE—breast cancer	1.57e-06	1.61e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—MTHFR—breast cancer	1.56e-06	1.59e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—SLC5A5—breast cancer	1.55e-06	1.59e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—NOS3—breast cancer	1.53e-06	1.56e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MAPK3—breast cancer	1.52e-06	1.56e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CAV1—breast cancer	1.52e-06	1.56e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—SLC2A1—breast cancer	1.5e-06	1.54e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NQO1—breast cancer	1.5e-06	1.54e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MYC—breast cancer	1.48e-06	1.52e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TGFB1—breast cancer	1.48e-06	1.52e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—AKT1—breast cancer	1.47e-06	1.5e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—EGFR—breast cancer	1.45e-06	1.49e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYP1B1—breast cancer	1.44e-06	1.47e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CAV1—breast cancer	1.43e-06	1.47e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—HSP90AA1—breast cancer	1.41e-06	1.45e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PIK3CB—breast cancer	1.41e-06	1.44e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PTGS2—breast cancer	1.4e-06	1.43e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PIK3CG—breast cancer	1.39e-06	1.42e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NCOA1—breast cancer	1.37e-06	1.41e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KRAS—breast cancer	1.37e-06	1.4e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—STK11—breast cancer	1.35e-06	1.39e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYP19A1—breast cancer	1.35e-06	1.39e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PIK3CG—breast cancer	1.31e-06	1.34e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PIK3CA—breast cancer	1.26e-06	1.29e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—COMT—breast cancer	1.26e-06	1.29e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTP1—breast cancer	1.25e-06	1.28e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—HMOX1—breast cancer	1.23e-06	1.27e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ITPR1—breast cancer	1.23e-06	1.26e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PIK3CD—breast cancer	1.22e-06	1.25e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TP53—breast cancer	1.22e-06	1.25e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PTEN—breast cancer	1.22e-06	1.25e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ALB—breast cancer	1.2e-06	1.23e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PIK3CA—breast cancer	1.19e-06	1.22e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ABCB1—breast cancer	1.19e-06	1.21e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—TYMS—breast cancer	1.16e-06	1.19e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—HRAS—breast cancer	1.16e-06	1.19e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—NOS3—breast cancer	1.15e-06	1.18e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PLA2G4A—breast cancer	1.15e-06	1.18e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NCOR1—breast cancer	1.15e-06	1.18e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTM1—breast cancer	1.15e-06	1.18e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PIK3CD—breast cancer	1.15e-06	1.18e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ALB—breast cancer	1.13e-06	1.16e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IL6—breast cancer	1.11e-06	1.14e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GPX1—breast cancer	1.1e-06	1.13e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYP1A1—breast cancer	1.09e-06	1.12e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—NOS3—breast cancer	1.08e-06	1.11e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ERCC2—breast cancer	1.08e-06	1.11e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PIK3CB—breast cancer	1.06e-06	1.09e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTGS2—breast cancer	1.05e-06	1.08e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—AKT1—breast cancer	1.03e-06	1.05e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—MTHFR—breast cancer	1.02e-06	1.04e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PIK3CB—breast cancer	1e-06	1.03e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTGS2—breast cancer	9.92e-07	1.02e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—AKT1—breast cancer	9.7e-07	9.94e-06	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CAV1—breast cancer	9.38e-07	9.61e-06	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTEN—breast cancer	9.18e-07	9.41e-06	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTEN—breast cancer	8.65e-07	8.87e-06	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PIK3CA—breast cancer	8.58e-07	8.8e-06	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PIK3CG—breast cancer	8.54e-07	8.76e-06	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PIK3CD—breast cancer	7.51e-07	7.7e-06	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ALB—breast cancer	7.41e-07	7.6e-06	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NOS3—breast cancer	7.09e-07	7.27e-06	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—AKT1—breast cancer	7.01e-07	7.19e-06	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PIK3CB—breast cancer	6.55e-07	6.71e-06	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTGS2—breast cancer	6.49e-07	6.65e-06	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PIK3CA—breast cancer	6.48e-07	6.64e-06	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PIK3CA—breast cancer	6.1e-07	6.26e-06	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTEN—breast cancer	5.66e-07	5.8e-06	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—AKT1—breast cancer	5.29e-07	5.42e-06	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—AKT1—breast cancer	4.99e-07	5.11e-06	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PIK3CA—breast cancer	3.99e-07	4.09e-06	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—AKT1—breast cancer	3.26e-07	3.34e-06	CbGpPWpGaD
